Entity > Corporation > US > New York City New York > Synlogic

About Synlogic

Synlogic is a clinical-stage biotechnology company developing drugs for metabolic and immunological diseases using its proprietary synthetic technology approach.

Synlogic Targets Areas of Unmet Medical Needs: Synlogic specifically targets four areas of unmet medical need: rare metabolic diseases, enteric hyperoxaluria, gout, and immunological and inflammatory diseases The company's lead programs target patients with rare genetic metabolic diseases such as phenylketonuria and secondary hyperoxaluria.

Collaborations and Partnerships: Synlogic is also collaborating with Roche in a research collaboration focused on the discovery of a novel synthetic biologic for the treatment of inflammatory bowel disease, and with Ginkgo Bioworks to include additional unpublished preclinical assets, combining Synlogic's approach to synthetic biotics with Ginkgo's codebase and foundry services.

Founded in 2014 by Synthetic Biology Experts: Synlogic was founded in 2014 by two of the world's leading synthetic biology experts, James Collins, PhD, and Tim Lu, MD, PhD, of the Massachusetts Institute of Technology. The company is made up of visionary scientists - pioneering biologists and genetic engineers working to transform drug discovery and disease treatment in a new way. Synlogic combines synthetic biology, a form of precision biological engineering, with the principles of traditional drug discovery to develop medicines for diseases that require new approaches.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Synlogic